Currently Viewing:
Currently Reading
What We're Reading: The ACA Fails the Working Poor
January 05, 2016 – AJMC Staff
What We're Reading: Health Insurers Offer Free Doctor's Visits
January 04, 2016 – AJMC Staff
Improving Precision and Outcomes of Cancer Surgery
January 04, 2016 – Surabhi Dangi-Garimella, PhD
Age Affects Breast Cancer Patients' Reaction to 2 Drugs
January 03, 2016 – Jackie Syrop
Older Women with Breast Cancer Survive Better with Treatment Therapy
January 02, 2016 – Priyam Vora
This Week in Managed Care: January 2, 2016
January 02, 2016
Clinical and Biomedical Research Still Lacks Diversity
January 01, 2016 – Priyam Vora
Readers Choose Top Healthcare News of 2015
January 01, 2016 – Laura Joszt
5 Things to Know About Biosimilars in the New Year
January 01, 2016 – Surabhi Dangi-Garimella, PhD

What We're Reading: The ACA Fails the Working Poor

AJMC Staff
What we're reading, January 5, 2016: A special report highlights how the working poor slip through the cracks of the Affordable Care Act; the FDA approved 51 drugs in 2015 with nearly half being first-in-class; and the Senate is expected to vote on President Obama's nomination for FDA commissioner next Tuesday.
Millions of Americans, the working poor, remain uninsured, especially if they live in one of the 20 states that hasn’t expanded Medicaid. A special report from USA Today examined how the Affordable Care Act affects these individuals and found that companies are getting around paying for insurance for workers by hiring contract workers. In addition, up to 20% of businesses have cut or plan to cut workers’ hours in order to avoid paying for their health benefits.

In 2015, the FDA approved 51 new drugs, which is the largest number since 1950. Notably, among those drugs approved were 20 first-in-class drugs. However, Forbes points out that this number from the FDA may be conservative, as 4 other drugs should merit first-in-class recognition. Including those drugs—Farydak, Unituxin, Kybella, and Natpara—would mean 47% of the drugs the FDA approved in 2015 were first-in-class.

On Tuesday, January 12, the Senate health committee will vote on President Obama’s nominee, Robert Califf, MD, to be the commissioner of the FDA. During hearings, some voiced concerns about his connections with drug companies. In particular, Democratic presidential hopeful Senator Bernie Sanders (I-Vt) said he would oppose the nomination. However, for the most part, Dr Califf’s nomination is expected to easily be approved, reported The Hill.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up